Merck/Lundbeck Gaboxadol NDA Planned For 2007; Merck Gets Fourth Phase III NME

The $270 mil. licensing deal with Lundbeck will help boost Merck's pipeline after two significant late-stage setbacks in 2003. The GABA-A receptor agonist gaboxadol would be Merck's entry into the sleep disorder market.